Randomized double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension

Kuan Rau Chiou, Chen Huan Chen, Philip Yu An Ding, Ying Tsung Chen, Chih Tai Ting, Jin Long Huang, Andrew H.T. Chiang, Chun Peng Liu, Chi Jen Tseng, Chia Ting Chao, Mau Song Chang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Irbesartan is a newly developed angiotensin II receptor antagonist. Its antihypertensive efficacy and safety in Taiwanese patients with mild to moderate hypertension remains to be determined. Methods: This was a multicenter, double-blind, randomized, parallel group study. One hundred and sixteen patients from three centers were enrolled. After a placebo lead-in period of 14 days, 55 patients (24-75 years-of-age) who had a mean seated diastolic blood pressure of 95 to 110 mmHg were randomized to once-daily treatment with irbesartan 150 mg or enalapril 10 mg. Doses were doubled at week 4 if trough seated diastolic blood pressure was 90 mmHg or more. Trough blood pressure was measured at zero, two, four and eight weeks of treatment. Results: Both treatments lowered blood pressure with no significant difference in efficacy between treatment groups. Irbesartan 150 mg to 300 mg provided reductions in trough seated systolic and diastolic blood pressures at week 8 of -16.5 mmHg and -7.2 mmHg, respectively, with 36% of patients having a favorable response. Similarly, enalapril 10 mg to 20 mg reduced systolic and diastolic blood pressure by -10.6 mmHg and -5.0 mmHg, respectively, with a response rate of 43%. Headache, malaise and dizziness were the major adverse reactions observed in both groups. The incidence of drug-related cough was significantly higher with enalapril (18%) than with irbesartan (0%). Conclusions: Irbesartan 150 mg to 300 mg once daily was as effective in lowering blood pressure as enalapril 10 mg to 20 mg once daily. Both irbesartan and enalapril were well tolerated, while there was a significantly lower incidence of cough with irbesartan compared with enalapril.

Original languageEnglish
Pages (from-to)368-376
Number of pages9
JournalChinese Medical Journal (Taipei)
Volume63
Issue number5
Publication statusPublished - May 1 2000
Externally publishedYes

Fingerprint

irbesartan
Enalapril
Blood Pressure
Hypertension
Therapeutics
Cough

Keywords

  • Angiotensin II blocker
  • Angiotensin-converting enzyme inhibitor
  • Enalapril
  • Hypertension
  • Irbesartan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chiou, K. R., Chen, C. H., Ding, P. Y. A., Chen, Y. T., Ting, C. T., Huang, J. L., ... Chang, M. S. (2000). Randomized double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. Chinese Medical Journal (Taipei), 63(5), 368-376.

Randomized double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. / Chiou, Kuan Rau; Chen, Chen Huan; Ding, Philip Yu An; Chen, Ying Tsung; Ting, Chih Tai; Huang, Jin Long; Chiang, Andrew H.T.; Liu, Chun Peng; Tseng, Chi Jen; Chao, Chia Ting; Chang, Mau Song.

In: Chinese Medical Journal (Taipei), Vol. 63, No. 5, 01.05.2000, p. 368-376.

Research output: Contribution to journalArticle

Chiou, KR, Chen, CH, Ding, PYA, Chen, YT, Ting, CT, Huang, JL, Chiang, AHT, Liu, CP, Tseng, CJ, Chao, CT & Chang, MS 2000, 'Randomized double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension', Chinese Medical Journal (Taipei), vol. 63, no. 5, pp. 368-376.
Chiou, Kuan Rau ; Chen, Chen Huan ; Ding, Philip Yu An ; Chen, Ying Tsung ; Ting, Chih Tai ; Huang, Jin Long ; Chiang, Andrew H.T. ; Liu, Chun Peng ; Tseng, Chi Jen ; Chao, Chia Ting ; Chang, Mau Song. / Randomized double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. In: Chinese Medical Journal (Taipei). 2000 ; Vol. 63, No. 5. pp. 368-376.
@article{18225ccd33f2447db0c12cf1717cec02,
title = "Randomized double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension",
abstract = "Background: Irbesartan is a newly developed angiotensin II receptor antagonist. Its antihypertensive efficacy and safety in Taiwanese patients with mild to moderate hypertension remains to be determined. Methods: This was a multicenter, double-blind, randomized, parallel group study. One hundred and sixteen patients from three centers were enrolled. After a placebo lead-in period of 14 days, 55 patients (24-75 years-of-age) who had a mean seated diastolic blood pressure of 95 to 110 mmHg were randomized to once-daily treatment with irbesartan 150 mg or enalapril 10 mg. Doses were doubled at week 4 if trough seated diastolic blood pressure was 90 mmHg or more. Trough blood pressure was measured at zero, two, four and eight weeks of treatment. Results: Both treatments lowered blood pressure with no significant difference in efficacy between treatment groups. Irbesartan 150 mg to 300 mg provided reductions in trough seated systolic and diastolic blood pressures at week 8 of -16.5 mmHg and -7.2 mmHg, respectively, with 36{\%} of patients having a favorable response. Similarly, enalapril 10 mg to 20 mg reduced systolic and diastolic blood pressure by -10.6 mmHg and -5.0 mmHg, respectively, with a response rate of 43{\%}. Headache, malaise and dizziness were the major adverse reactions observed in both groups. The incidence of drug-related cough was significantly higher with enalapril (18{\%}) than with irbesartan (0{\%}). Conclusions: Irbesartan 150 mg to 300 mg once daily was as effective in lowering blood pressure as enalapril 10 mg to 20 mg once daily. Both irbesartan and enalapril were well tolerated, while there was a significantly lower incidence of cough with irbesartan compared with enalapril.",
keywords = "Angiotensin II blocker, Angiotensin-converting enzyme inhibitor, Enalapril, Hypertension, Irbesartan",
author = "Chiou, {Kuan Rau} and Chen, {Chen Huan} and Ding, {Philip Yu An} and Chen, {Ying Tsung} and Ting, {Chih Tai} and Huang, {Jin Long} and Chiang, {Andrew H.T.} and Liu, {Chun Peng} and Tseng, {Chi Jen} and Chao, {Chia Ting} and Chang, {Mau Song}",
year = "2000",
month = "5",
day = "1",
language = "English",
volume = "63",
pages = "368--376",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "5",

}

TY - JOUR

T1 - Randomized double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension

AU - Chiou, Kuan Rau

AU - Chen, Chen Huan

AU - Ding, Philip Yu An

AU - Chen, Ying Tsung

AU - Ting, Chih Tai

AU - Huang, Jin Long

AU - Chiang, Andrew H.T.

AU - Liu, Chun Peng

AU - Tseng, Chi Jen

AU - Chao, Chia Ting

AU - Chang, Mau Song

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Background: Irbesartan is a newly developed angiotensin II receptor antagonist. Its antihypertensive efficacy and safety in Taiwanese patients with mild to moderate hypertension remains to be determined. Methods: This was a multicenter, double-blind, randomized, parallel group study. One hundred and sixteen patients from three centers were enrolled. After a placebo lead-in period of 14 days, 55 patients (24-75 years-of-age) who had a mean seated diastolic blood pressure of 95 to 110 mmHg were randomized to once-daily treatment with irbesartan 150 mg or enalapril 10 mg. Doses were doubled at week 4 if trough seated diastolic blood pressure was 90 mmHg or more. Trough blood pressure was measured at zero, two, four and eight weeks of treatment. Results: Both treatments lowered blood pressure with no significant difference in efficacy between treatment groups. Irbesartan 150 mg to 300 mg provided reductions in trough seated systolic and diastolic blood pressures at week 8 of -16.5 mmHg and -7.2 mmHg, respectively, with 36% of patients having a favorable response. Similarly, enalapril 10 mg to 20 mg reduced systolic and diastolic blood pressure by -10.6 mmHg and -5.0 mmHg, respectively, with a response rate of 43%. Headache, malaise and dizziness were the major adverse reactions observed in both groups. The incidence of drug-related cough was significantly higher with enalapril (18%) than with irbesartan (0%). Conclusions: Irbesartan 150 mg to 300 mg once daily was as effective in lowering blood pressure as enalapril 10 mg to 20 mg once daily. Both irbesartan and enalapril were well tolerated, while there was a significantly lower incidence of cough with irbesartan compared with enalapril.

AB - Background: Irbesartan is a newly developed angiotensin II receptor antagonist. Its antihypertensive efficacy and safety in Taiwanese patients with mild to moderate hypertension remains to be determined. Methods: This was a multicenter, double-blind, randomized, parallel group study. One hundred and sixteen patients from three centers were enrolled. After a placebo lead-in period of 14 days, 55 patients (24-75 years-of-age) who had a mean seated diastolic blood pressure of 95 to 110 mmHg were randomized to once-daily treatment with irbesartan 150 mg or enalapril 10 mg. Doses were doubled at week 4 if trough seated diastolic blood pressure was 90 mmHg or more. Trough blood pressure was measured at zero, two, four and eight weeks of treatment. Results: Both treatments lowered blood pressure with no significant difference in efficacy between treatment groups. Irbesartan 150 mg to 300 mg provided reductions in trough seated systolic and diastolic blood pressures at week 8 of -16.5 mmHg and -7.2 mmHg, respectively, with 36% of patients having a favorable response. Similarly, enalapril 10 mg to 20 mg reduced systolic and diastolic blood pressure by -10.6 mmHg and -5.0 mmHg, respectively, with a response rate of 43%. Headache, malaise and dizziness were the major adverse reactions observed in both groups. The incidence of drug-related cough was significantly higher with enalapril (18%) than with irbesartan (0%). Conclusions: Irbesartan 150 mg to 300 mg once daily was as effective in lowering blood pressure as enalapril 10 mg to 20 mg once daily. Both irbesartan and enalapril were well tolerated, while there was a significantly lower incidence of cough with irbesartan compared with enalapril.

KW - Angiotensin II blocker

KW - Angiotensin-converting enzyme inhibitor

KW - Enalapril

KW - Hypertension

KW - Irbesartan

UR - http://www.scopus.com/inward/record.url?scp=6744248838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6744248838&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 368

EP - 376

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 5

ER -